2023 was another tough year for biotech initial public offerings, but there are some signs that 2024 could see the market open up again. After a more upbeat mood at the J.P. Morgan conference (JPM) and signs of improving macro-economic stability, the next big test for biotech is a trio of planned flotations. These will come from gene-editing specialist Metagenomi and cancer-focused start-ups ArriVent Biopharma and CG Oncology.
After An Upbeat J.P. Morgan, Three Biopharmas Look To Kick Off IPOs For 2024
Gene editing company Metagenomi and two oncology biopharmas will test the IPO waters soon – with hopes this could pave the way for others.
More from Business
• By
Industry lobbied for pharmaceuticals to be exempt from Trump’s sweeping US tariffs and the effort appears to have paid off. J&J, Lilly and Merck & Co. even got shout outs.
• By
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
More from Scrip
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.